Pacira BioSciencesFRA:82P +6.74%74 Piotroski F-Score is 8 as of Jun. 25, 2026, which is 60% above its 10-year median of 5.00. GuruFocus rates FRA:82P with a GF Score™ of 74/100 and a GF Value™ of €25.35. The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Pacira BioSciences ranks better than 98.37% on this metric.
Good Sign:
Piotroski F-Score is 8, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Pacira BioSciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Pacira BioSciences's Piotroski F-Score or its related term are showing as below:
FRA:82P'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 5 Max: 8
Current: 8
During the past 13 years, the highest Piotroski F-Score of Pacira BioSciences was 8. The lowest was 3. And the median was 5.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Pacira BioSciences Piotroski F-Score Related Terms
Pacira BioSciences Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:82P vs ETON, AMPH, ESPR: Piotroski F-Score Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Pacira BioSciences's current Net Income (TTM) was 4.3.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Pacira BioSciences's return on assets of this year was 0.00296116. Pacira BioSciences's return on assets of last year was -0.0631227.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Pacira BioSciences's gearing of this year was 0.2877969. Pacira BioSciences's gearing of last year was 0.26891633.
==> Last year is lower than this year ==> Score 0.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Pacira BioSciences's current ratio of this year was 4.73364789. Pacira BioSciences's current ratio of last year was 2.41463348.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Pacira BioSciences's number of shares in issue this year was 40.91. Pacira BioSciences's number of shares in issue last year was 46.526.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Pacira BioSciences's gross margin of this year was 0.79327845. Pacira BioSciences's gross margin of last year was 0.77625439.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Pacira BioSciences's asset turnover of this year was 0.43028844. Pacira BioSciences's asset turnover of last year was 0.44783974.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
0
+
1
+
1
+
1
+
0
=
7
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Pacira BioSciences has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.
Pacira BioSciences (FRA:82P) has a Piotroski F-Score of 8 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Pacira BioSciences and its competitors. This is 60% above median its historical median of 5.00. Over the past decade, Pacira BioSciences' Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Pacira BioSciences ranks #16 out of 981 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is Pacira BioSciences' Piotroski F-Score too high?
Pacira BioSciences' current Piotroski F-Score of 8 is 60% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Pacira BioSciences' value of 8 is 60% above this industry median. Based on the distribution chart, Pacira BioSciences ranks #16 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Pacira BioSciences has a GF Score™ of 74/100, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Piotroski F-Score compare to ETON and AMPH?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #16 out of 981 companies for Piotroski F-Score. This places Pacira BioSciences in the top 2% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Pacira BioSciences' value of 8 is 60% above this benchmark. Historically, Pacira BioSciences' own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Pacira BioSciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacira BioSciences's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Piotroski F-Score is 8, which is 60% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Pacira BioSciences (FRA:82P) has a current Piotroski F-Score of 8. The stock's GF Value™ is €25.35, compared to a current price of €20.60 — trading 18.7% below its estimated fair value. The current Piotroski F-Score is 8, which is 60% above median its 10-year median of 5.00 and 60% above the Drug Manufacturers industry median of 5.00. Pacira BioSciences' overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Pacira BioSciences (FRA:82P), the current Piotroski F-Score is 8 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (FRA:82P) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of €20.60 is trading 18.7% below its estimated GF Value™ of €25.35.
Key valuation signals for FRA:82P:
Piotroski F-Score: 8 (60% above median its 10-year median of 5.00)
GF Value™: €25.35 vs. price of €20.60 (18.7% below fair value)
Industry Position: 60% above the Drug Manufacturers median (#16 of 981)
No single metric tells the full story. See the FRA:82P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
74GF Score
Get the complete analysis for FRA:82P
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:82P has been successfully added to your 
